Literature DB >> 24839504

Uptake of neoadjuvant chemotherapy for invasive bladder cancer.

Wassim Kassouf1.   

Abstract

Entities:  

Year:  2014        PMID： 24839504      PMCID： PMC4001665          DOI： 10.5489/cuaj.2077

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  10 in total

1.  Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924.

Authors:  C N Sternberg; P H de Mulder; J H Schornagel; C Théodore; S D Fossa; A T van Oosterom; F Witjes; M Spina; C J van Groeningen; C de Balincourt; L Collette
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

2.  Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience.

Authors:  Faysal A Yafi; Armen G Aprikian; Joseph L Chin; Yves Fradet; Jonathan Izawa; Eric Estey; Adrian Fairey; Ricardo Rendon; Ilias Cagiannos; Louis Lacombe; Jean-Baptiste Lattouf; David Bell; Darrel Drachenberg; Wassim Kassouf
Journal:  BJU Int       Date:  2010-12-16       Impact factor: 5.588

3.  Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration.

Authors: 
Journal:  Eur Urol       Date:  2005-04-21       Impact factor: 20.096

Review 4.  Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.

Authors:  Arnulf Stenzl; Nigel C Cowan; Maria De Santis; Markus A Kuczyk; Axel S Merseburger; Maria José Ribal; Amir Sherif; J Alfred Witjes
Journal:  Eur Urol       Date:  2011-03-23       Impact factor: 20.096

5.  Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.

Authors:  Hans von der Maase; Lisa Sengelov; James T Roberts; Sergio Ricci; Luigi Dogliotti; T Oliver; Malcolm J Moore; Annamaria Zimmermann; Michael Arning
Journal:  J Clin Oncol       Date:  2005-07-20       Impact factor: 44.544

6.  Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC.

Authors:  R Millikan; C Dinney; D Swanson; P Sweeney; J Y Ro; T L Smith; D Williams; C Logothetis
Journal:  J Clin Oncol       Date:  2001-10-15       Impact factor: 44.544

7.  Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base.

Authors:  Phillip J Gray; Stacey A Fedewa; William U Shipley; Jason A Efstathiou; Chun Chieh Lin; Anthony L Zietman; Katherine S Virgo
Journal:  Eur Urol       Date:  2012-11-19       Impact factor: 20.096

8.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Authors:  H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2003-08-28       Impact factor: 91.245

9.  Refining patient selection for neoadjuvant chemotherapy before radical cystectomy.

Authors:  Stephen H Culp; Rian J Dickstein; H Barton Grossman; Shanna M Pretzsch; Sima Porten; Siamak Daneshmand; Jie Cai; Susan Groshen; Arlene Siefker-Radtke; Randall E Millikan; Bogdan Czerniak; Neema Navai; Matthew F Wszolek; Ashish M Kamat; Colin P N Dinney
Journal:  J Urol       Date:  2013-07-30       Impact factor: 7.450

10.  Improving the outcome of patients with muscle invasive urothelial carcinoma of the bladder with neoadjuvant gemcitabine/cisplatin chemotherapy: A single institution experience.

Authors:  Faraj El-Gehani; Scott North; Sunita Ghosh; Peter Venner
Journal:  Can Urol Assoc J       Date:  2014-03       Impact factor: 1.862
  10 in total
  1 in total

1.  Dose dense MVAC prior to radical cystectomy: a real-world experience.

Authors:  Homayoun Zargar; Jay B Shah; Elisabeth E Fransen van de Putte; Kylea R Potvin; Kamran Zargar-Shoshtari; Bas W van Rhijn; Siamak Daneshmand; Jeff M Holzbeierlein; Philippe E Spiess; Eric Winquist; Simon Horenblas; Colin Dinney; Peter C Black; Wassim Kassouf
Journal:  World J Urol       Date:  2017-06-17       Impact factor: 4.226
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.